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Abstract
Background: Hepatitis C virus (HCV) is the leading cause of liver fibrosis, cirrhosis and hepatocellular carcinoma. It is
believed that continuous liver cell apoptosis contributes to HCV pathogenesis. Recent studies have shown that HCV
infection can sensitize host cells to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis, but the mechanism by
which HCV regulates the TRAIL pathway remains unclear.
Methods and Results: Using a sub-genomic replicon and full length virus, JFH-1, we demonstrate that HCV can sensitize
host cells to TRAIL-induced apoptosis by up-regulating two TRAIL receptors, death receptor 4 (DR4) and death receptor 5
(DR5). Furthermore, the HCV replicon enhanced transcription of DR5 via Sp1, and the HCV-mediated up-regulation of DR4
and DR5 required MEK1 activity. HCV infection also stimulated the activity of MEK1, and the inhibition of MEK1 activity or
the knockdown of MEK1 increased the replication of HCV.
Conclusions: Our studies demonstrate that HCV replication sensitizes host cells to TRAIL-induced apoptosis by up-
regulating DR4 and DR5 via a MEK1 dependent pathway. These findings may help to further understand the pathogenesis
of HCV infection and provide a therapeutic target.
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Introduction
TNF-related apoptosis-inducing ligand (TRAIL), also known as
Apo2L, is a member of the tumor necrosis factor (TNF) super
family [1]. However, in contrast to TNF-a and FasL, TRAIL
typically induces apoptosis in transformed cells but not in healthy
cells [2]. Furthermore, recent studies have shown that TRAIL also
induces apoptosis in virus-infected cells, including cells infected
with hepatitis B virus, hepatitis C virus (HCV), human immuno-
deficiency virus, and respiratory syncytial virus [3,4,5,6,7]. Thus,
TRAIL may function as an immune surveillance factor by
selectively killing transformed and virus-infected cells. There are
four specific TRAIL receptors on the cell membrane, death
receptor 4 (DR4; also known as TRAIL-R1 or TNFRSF10A),
death receptor 5 (DR5; also known as TRAIL-R2, KILLER, or
TNFRSF10B), decoy receptor 1 (DcR1; also known as TRAIL-
R3, TRID, or TNFRSF10C) and decoy receptor 2 (DcR2; also
known as TRAIL-R4 or TNFRSF10D). DcR1 and DcR2 are two
decoy receptors that contain a TRAIL-binding domain but lack
a functional death domain. TRAIL can also bind to osteoprote-
gerin, which is a soluble TNF receptor family member; however, it
has low binding affinity at physiological conditions [8]. The
binding of TRAIL to DR4 or DR5 results in receptor
trimerization and cell apoptosis via the recruitment of Fas-
associated death domain (FADD) to the C terminus of the
receptors. FADD then recruits an apoptosis-initiator caspase
(caspase 8 or caspase 10) via its death effecter domain to form the
death-inducing signaling complex, which allows for auto activation
of caspases [9]. The downstream signaling of activated caspase 8
or 10 is dependent on the cell type. In type 1 cells, caspase 3 is
activated and cleaves many cellular proteins to induce apoptosis.
In type 2 cells, the apoptosis signal is augmented by the
mitochondrial pathway, which involves the activation of caspase
9 following the loss of the mitochondrial membrane potential and
Apaf-1 activation [10].
HCV belongs to the Flaviviridae family. Its genome is an
enveloped positive RNA of 9.6 kb in length, containing one large
open reading frame (ORF). The large ORF is translated into one
polyprotein which is cleaved into ten mature proteins including
core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B
protein. The core protein has a frame shift variant called the F
protein [11]. Up to 3% of the global population is HCV positive,
and approximately 80% of infected patients develop a chronic
infection [12]. HCV-infected patients are typically treated with
pegylated IFN-a plus ribavirin. However, half of the individuals
infected with genetype 1 do not achieve sustained viral clearance
[13]. Liver cell apoptosis has been observed in HCV-infected
patients, and accumulating evidence suggests that liver cell
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is believed that liver damage, at least in part, causes fibrosis of the
liver [15]. Although a direct cytopathic effect of a high HCV viral
load has also been reported [16], the current prevailing view is that
the apoptosis of liver cells in chronically infected HCV patients is
initiated by the host innate and adaptive immune response. Many
studies examining HCV and apoptosis have been reported.
Several of these studies focused on a single HCV protein, and
other studies used a cell culture replicon. However, the results
from these studies have been conflicting, and there is currently no
consensus regarding the role of HCV in liver cell apoptosis [17].
Previous studies have reported that TRAIL and its functional
receptors: DR4 and DR5 are up-regulated in the liver of HCV-
infected patients [18,19] and that the expression levels of DR4 and
DR5 are elevated in some cases of HCV-related hepatocellular
carcinoma (HCC) [20]. However, it has also been reported that
the expression of DR4 or DR5 is not altered in the liver during
HCV-mediated cirrhosis [21]. In cell culture system, it has been
shown that the HCV core protein can enhance TRAIL-induced
apoptosis in Huh7 cells, a hepatoma cell line normally insensitive
to TRAIL [22]. Furthermore, it has also been recently shown that
infection with the full-length virus JFH-1 can sensitize Huh7.5 cells
to TRAIL-induced apoptosis without changing the expression
level of the TRAIL receptors [4]. However, another study
demonstrates that JFH-1 infection can trigger the expression of
TRAIL and its functional receptors in a cell culture system [23].
Taken together, it still remains controversial if TRAIL receptors
are elevated in HCV-infected cells, and the molecular mechanism
that underlies the up-regulation of TRAIL receptors has not been
examined to date.
A stable cell line, 9–13, that contains an HCV 1b sub-genomic
replicon that lacks the genes for all structural proteins and the NS2
protein has been derived from Huh7 cells [24]. The first infectious
HCV cell culture model, JFH-1, was developed by Dr. Wakita in
2005 [25]. These two HCV cell culture models have greatly aided
HCV research. In the current study, we found that 9–13 cells were
more sensitive to TRAIL-induced apoptosis than Huh7 cells and
that the expression of DR4 and DR5 was significantly higher in 9–
13 cells at both the mRNA and protein levels when compared with
Huh7 cells. Elimination of the HCV replicon in the 9–13 cells
decreased the expression of DR4 and DR5. Similarly, the
expression level of DR4 and DR5 was elevated in Huh 7.5.1
cells when infected with JFH-1. Furthermore, HCV increased the
transcription of DR5 via the transcription factor Sp1. HCV
replication also stimulated the activity of MEK1 and MEK1
activity was required for DR4 and DR5 up-regulation in both 9–
13 cells and JFH-1 infected Huh7.5.1 cells. Importantly, inhibition
the activity or expression of MEK1 increased the replication of
HCV. Together, these results demonstrate that HCV replication
up-regulates DR4 and DR5 via a MEK1-dependent pathway,
which results in the sensitization of host cells to TRAIL-induced
apoptosis. These results suggest that MEK1 may be a negative
regulator of HCV replication.
Results
HCV replicon-containing cells are more sensitive to
TRAIL-induced apoptosis than naive cells
TRAIL has the ability to induce apoptosis in some transformed
cells [2]. However, Huh7 cells, a HCC cell line, are resistant to
TRAIL-induced apoptosis [22]. Therefore, we tested if 9–13 cells
(designated ‘‘HCV REP’’ in all figures), which were derived from
the Huh7 cell line and contain a HCV 1b sub genomic replicon
(Fig. 1A), were sensitive to TRAIL. When exposed to 25–100 ng/
mL TRAIL for 2 hr, a large proportion of 9–13 cells underwent
apoptosis, whereas only a small fraction of the TRAIL-treated
Huh7 cells underwent apoptosis (Fig. 1B). Furthermore, the
activity of caspase 3 was much greater in 9–13 cells than in Huh7
cells (Fig. 1C), indicating that the HCV replicon sensitized the host
cells to TRAIL-induced apoptosis. The cell death induced by
TRAIL was dependent on caspase activity because pre-treating 9–
13 cells with the pan-caspase inhibitor, Z-VAD-FMK, completely
abolished TRAIL-induced apoptosis (Fig. 1D).
DR4 and DR5 are both up-regulated by HCV replication
We evaluated the mRNA levels of the TRAIL receptors using
real-time PCR and found that the mRNA levels of DR4 and DR5
were higher in 9–13 cells when compared with Huh7 cells.
Moreover, there was no significant change in the mRNA levels of
DcR1 and DcR2 (Fig. 2A). Western blot analyses confirmed that
DR4 and DR5 were up-regulated in 9–13 cells (Fig. 2B). The
activity of the DR4 and DR5 promoters was then tested in both
cell lines. The DR4 and DR5 promoter activities were significantly
higher in 9–13 cells than in Huh7 cells (Fig. 2C). To verify that the
up-regulation of DR4 and DR5 was due to HCV replicon
replication, we eliminated the HCV replicon from 9–13 cells and
analyzed the expression of DR4 and DR5. We treated 9–13 cells
with 100 IU/mL IFN-a and cultured the cells for four passages.
As shown in Fig. 3A, the replication of HCV was completely
inhibited after the IFN-a treatment, and HCV RNA was barely
detected by using real-time PCR (data not shown). These IFN-
a treated cells were designated HCV-cured cells. The expression
of DR4 and DR5 was significantly decreased in HCV-cured cells
when compared with 9–13 cells (Fig. 3A). We analyzed the
sensitivity of the HCV-cured cells to TRAIL-induced apoptosis
and found that the HCV-cured cells were less sensitive to TRAIL
when compared with 9–13 cells (Fig. 3B). These results
demonstrate that HCV replication up-regulates DR4 and DR5
and sensitizes host cells to TRAIL-induced apoptosis. To further
confirm the elevation of DR4 and DR5 levels is resulted from
HCV infection, we infected Huh7.5.1 cells with JFH-1 and
measured the expression of DR4 and DR5 1, 2, 3 days post-
infection by western blotting. As shown in Fig. 4A, the expression
of DR4 and DR5 was significantly up-regulated at the 3
rd day
post-infection. Similar up-regulation was observed at mRNA level
at the 3
rd day post-infection (Fig. 4B). The expression of DR4 and
DR5 had a modest decrease at the 1
st day post-infection (Fig. 4A),
this result suggests that HCV may have some method to inhibit the
expression of DR4 and DR5, in order to prevent host cell
apoptosis at the early period of infection. However, more
experiments are needed to confirm this observation in future
study. In addition, the promoter activity of DR4 and DR5 were
significantly higher in the JFH-1 infected cells (Fig. 4C). And
correlated with the up-regulation of TRAIL receptors, the infected
cells were more sensitive to TRAIL-induced apoptosis (Fig. 4D).
HCV-mediated up-regulation of DR4 transcription
depends on the 2464 to 2384 bp region of the DR4
promoter
We further studied the mechanism underlying the regulation of
DR4 expression by HCV. The following reporter plasmids
containing different regions of the DR4 promoter were con-
structed: pDR4/2632, pDR4/2541, pDR4/2464, pDR4/
2384, and pDR4/2349. The promoter activity of these plasmids
was compared in 9–13 and Huh7 cells. As shown in Fig. 5A, the
80 bp fragment between 2464 and 2384 bp of the DR4
promoter region was critical for DR4 transcription. A previous
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regulates the transcription of DR4 [26]. However, a point
mutation in this AP-1 binding site (Fig. 5E) failed to influence
the promoter activity of DR4 in 9–13 cells (Fig. 5B).
HCV replicon enhances transcription of DR5 via Sp1
To elucidate the mechanism underlying HCV-mediated regu-
lation of DR5, we constructed several reporter plasmids containing
different regions of the DR5 promoter (pDR5/2560, pDR5/
2220, and pDR5/2115). The promoter activity of these plasmids
was compared in 9–13 and Huh7 cells. As shown in Fig. 5C, the
2220 bp fragment of the DR5 promoter was sufficient for
promoter activity. These results suggest that the increased DR5
expression caused by the HCV sub-genomic replicon is dependent
on the DR5 promoter and that the 2220 bp fragment of the
promoter is the minimal promoter. The 2195/2189 and 2149/
2143 sites of the promoter have been shown to be two Sp1
binding sites, which are important for the transcription of DR5
[27]. A luciferase assay was then performed with the following
mutant constructs: pDR5/2560/2195m, pDR5/2560/2149m,
and pDR5/2560/dm (pDR5/2560/2195m,2149m) (Fig. 5E).
Mutation of the each of the Sp1 binding sites decreased the activity
of the promoter, and the pDR5/2560/dm had no promoter
activity (Fig. 5C). To further confirm that Sp1 is required for
transcription of DR5 in 9–13 cells, we transfected 9–13 cells with
a siRNA targeting Sp1. The expression of DR5 was detected using
real-time PCR and western blot analyses 2 days post-transfection.
The RNA and protein levels of DR5 were decreased when
compared with cells transfected with control siRNA (Fig. 5F).
These results suggest that the transcription of DR5 is controlled by
Sp1 in 9–13 cells and that the HCV sub-genomic replicon
enhances the transcription of DR5 via Sp1. We then co-
transfected a plasmid expressing individual HCV nonstructural
protein and a plasmid containing either DR4/2632 or DR5/
2560 into Huh7 cells. Expression of the NS3/4, NS4B or NS5A
protein increased DR5 promoter activity, and expression of the
NS3/4A or NS4B protein increased DR4 promoter activity.
However, the luciferase activity was too low, suggesting that the
expression of these individual nonstructural proteins barely
activates the DR4 and DR5 promoters (Fig. 5G).
HCV-mediated up-regulation of DR4 and DR5 requires
MEK1 activity
Sp1 is a member of a large family of transcription factors
characterized by their affinity for GC-rich motifs. These
transcription factors control the basal expression of housekeeping
genes and genes lacking or containing a TATA box [28]. Sp1
activity is mainly regulated by post-translational modifications,
with phosphorylation the most studied post-translational modifi-
cation. Recent studies have shown that MAPKs, such as ERK and
JNK, can phosphorylate Sp1 [29,30,31].
Macdonald and colleagues (2003, 2005) have reported that the
HCV NS5A protein can inhibit AP-1 activity by perturbing Ras-
ERK signaling [32,33]. Because the DR5 promoter contains two
Sp1 binding sites, we studied the role of MAPKs in the HCV
replicon-induced up-regulation of DR5. When compared with
Huh7 cells, the AP-1 and Sp1 activity was increased in 9–13 cells,
while the NF-kB activity was not changed (Fig. 6A). Furthermore,
the over expression of MEK1 in Huh7 cells enhanced the
transcription activity of AP-1 and Sp1, and the over expression of
MEKK1 in Huh7 cells increased the transcription activity of AP-1
(Fig. 6B). These results suggest that HCV replication may activate
MAPKs.
Figure 1. HCV replicon sensitizes host cells to TRAIL-induced
and caspase-dependent apoptosis. (A) Cell lysates from HCV
replicon-containing cells (9–13) and Huh7 cells were subjected to
western blot analyses using a rabbit polyclonal antibody against HCV
NS3/4A. (B) Huh7 and 9–13 cells were treated with TRAIL at different
concentrations (10 ng/mL, 20 ng/mL, 50 ng/mL or 100 ng/mL) for 2 hr
and stained with annexin V and PI. The proportion of apoptotic cells
was measured using flow cytometry. (C) Huh7 and 9–13 cells were
treated with 50 ng/mL TRAIL for 2 hr, and caspase 3 activity was
measured using a Caspase 3 Activity Assay Kit. (D) 9–13 cells were
treated with 20 mM Z-VAD-FMK (a pan-caspase inhibitor) or DMSO for
1 hr and subsequently treated with 50 ng/mL TRAIL for 2 hr. The mock-
treated samples were untreated 9–13 cells. The proportion of apoptotic
cells was measured using flow cytometry after the cells were stained
with annexin V and PI. The data are presented with the SD from three
independent experiments, and statistical significance was calculated by
t test or two-way ANOVA, * indicates a p value less than 0.05.
doi:10.1371/journal.pone.0037700.g001
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activates ERK-1 and ERK-2 [34], which can activate AP-1 [29].
Additionally, MEKK1 can activate JNK [35], which also activates
AP-1. Therefore, we investigated the relationship between the
MAPKs and the expression of the TRAIL receptors. We co-
transfected pDR4/2464 or pDR4/2384 with plasmids expres-
sing MEK1 or MEKK1 into Huh7 cells and found that over
expression of MEK1 increased the activity of pDR4/2464, but
did not affect the activity of pDR4/2384. Similarly, over
expression of MEK1 increased the activity of the DR5 promoter
pDR5/2560 but not the pDR5/2560dm. In contrast, MEKK1
only slightly increased the DR4 promoter activity and did not
affect the DR5 promoter activity (Fig. 6C). These results suggest
that MEK1/ERK, but not MEKK1/JNK, is involved in the
regulation of DR4 and DR5 expression. Furthermore, the region
between 2464 and 2384 in the DR4 promoter and the Sp1
binding sites in the DR5 promoter were required for MEK1-
mediated regulation of DR4 and DR5 activity.
Activation of MEK1 occurs via phosphorylation of two serine
residues at positions 217 and 221 [36]. Using an antibody against
phosphorylated MEK1 (Ser217/221), we detected the phosphor-
ylated form of MEK1 in 9–13 cells using western blot analyses. As
shown in Fig. 7A, phosphorylation level of MEK1 was higher in 9–
13 cells when compared with Huh7 cells, suggesting that HCV
replication activates MEK1. Furthermore, we investigated wheth-
er inhibition of MEK1/ERK or MEKK1/JNK reversed the
HCV-mediated up-regulation of DR4 and DR5. Treatment with
PD98059, a MEK1-specific inhibitor, reversed the high expression
of DR4 and DR5 in 9–13 cells, but a specific inhibitor of JNK,
SP600125, had no effect (Fig. 7C). Knockdown of MEK1 using
siRNA also decreased the expression of DR4 and DR5 (Fig. 7D).
Moreover, JFH-1 infection stimulated MEK1 activity in Huh7.5.1
Figure 2. HCV replication up-regulates DR4 and DR5. (A) The mRNA level of DR4, DR5, DcR1, and DcR2 in 9–13 and Huh7 cells was measured
using real-time RT-PCR. (B) Huh7 and 9–13 cell lysates were subjected to western blot analyses using a rabbit polyclonal antibody against DR4 or DR5.
(C) The DR4 reporter plasmid (DR4/21156; 100 ng) or DR5 reporter plasmid (DR5/21192; 100 ng) was co-transfected with the Renilla luciferase
reporter plasmid (100 ng) into 9–13 or Huh7 cells cultured in a 24-well plate. After 2 days, the cells were harvested, and the luciferase activity was
measured. (A and C) The data from the 9–13 cells were normalized to Huh7 cells to directly show the fold induction caused by HCV. The data are
presented with the SD from three independent experiments, and statistical significance was calculated by t test, * indicates a p value less than 0.05.
doi:10.1371/journal.pone.0037700.g002
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infection reversed the HCV-mediated up-regulation of DR4 and
DR5 (Fig. 7E). Taken together, these data indicate that MEK1 has
a critical role in the HCV-mediated up-regulation of DR4 and
DR5. To confirm that knockdown of MEK1 could decrease the
sensitivity to TRAIL-induced apoptosis, we tested other four pairs
of siRNA of MEK1, and choose two of them to perform the next
experiment (Fig. 7F). As shown in Fig. 7G and 7H, knockdown of
MEK1 weakened the apoptosis induced by TRAIL both in 9–13
cells and JFH-1 infected Huh7.5.1 cells.
Inhibition of MEK1 activity by its specific inhibitor, PD98059,
can enhance the replication of HCV [37,38]. Therefore, we tested
if inhibition of MEK1 enhanced HCV replication. As shown in
Fig. 8, both PD98059 and a MEK1-specific siRNA increased JFH-
1 replication in Huh7.5.1 cells. Together, these results suggest that
MEK1 may be stimulated to inhibit HCV replication when cells
are infected by HCV.
Discussion
The relationship between HCV infection and TRAIL and its
receptors has been previously studied. Clinical evidence has shown
that HCV infection is related to the up-regulation of DR4 and
DR5. Saitou et al. (2005) have reported that TRAIL, DR4 and
DR5 are over expressed in the cytoplasm and on the surface of
hepatocytes from patients chronically infected with HCV [18].
Volkmann and colleagues (2007) reported that TRAIL alone
triggers massive apoptosis and caspase activation in tissue explants
from patients with liver steatosis or HCV infection and that the
enhanced sensitivity of diseased liver is associated with the
increased expression of DR4 and DR5 [19]. Yano et al. (2003)
reported that some HCV-related HCC cases have increased
caspase 3 activity and expression of DR4 and DR5 in the tumor
tissue [20]. However, Mundt et al. (2003) reported that DR4 and
DR5 are not up-regulated in chronic hepatitis-associated cirrhosis
[21]. It also remains controversial if TRAIL receptors are up-
regulated by HCV infection in a cell culture system. Lan et al.
(2008) reported that DR4 and DR5 are not up-regulated in JFH-1
Figure 3. Up-regulation of DR4 and DR5 is HCV replication-
dependent. (A) Lysates from Huh7, 9–13 and HCV-cured cells were
subjected to western blot analysis using rabbit polyclonal antibodies
against HCV NS3/4A, DR4 or DR5. (B) Huh7, 9–13 and HCV-cured cells
were treated with 25 and 50 ng/mL TRAIL for 2 hr, and the proportion
of apoptotic cells was measured using flow cytometry after the cells
were stained with annexin V and PI. The data are presented with the SD
from three independent experiments, and statistical significance was
calculated by two-way ANOVA, * indicates a p value less than 0.05.
doi:10.1371/journal.pone.0037700.g003
Figure 4. JFH-1 infection up-regulates the expression of DR4 and DR5. (A) Western blot analysis was performed to measure the expression
of DR4 and DR5 in Huh7.5.1 cells infected with JFH-1 1, 2, 3 days post-infection (MOI 0.02). (B) Real-time PCR was performed to measure the mRNA
levels of DR4 and DR5 in Huh7.5.1 cells infected with JFH-1 (MOI 0.02) 3 days post-infection. (C) The DR4 reporter plasmid (DR4/21156; 100 ng) or
DR5 reporter plasmid (DR5/21192; 100 ng) was co-transfected with the Renilla luciferase reporter plasmid (50 ng) into Huh7.5.1 cells, 6 hr later, cells
were infected with JFH-1 (MOI 0.5). After 3 days, the cells were harvested, and the luciferase activity was measured. The data from the infected cells
were normalized to Huh7.5.1 cells to directly show the fold induction caused by HCV. (D) Huh7.5.1 cells were infected with JFH-1 (MOI 0.5), 3 days
later, cells were treated with indicated concentration of TRAIL for 2 hr, and stained with annexin V and PI. The proportion of apoptotic cells was
measured using flow cytometry. The data are presented with the SD from three independent experiments, and statistical significance was calculated
by t test or two-way ANOVA, * indicates a p value less than 0.05.
doi:10.1371/journal.pone.0037700.g004
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37700Figure 5. Transcriptional analysis of DR4 and DR5 in 9–13 cells. (A and C) Luciferase reporter plasmids (100 ng) containing different regions
of the (A) DR4 or (C) DR5 promoter and the Renilla luciferase reporter plasmid (100 ng) were co-transfected into 9–13 or Huh7 cells. 2 days post-
transfection, the cells were harvested, and luciferase activity was measured. (B and D) The indicated reporter plasmids (100 ng) illustrated in (E) were
co-transfected with the Renilla luciferase reporter plasmid (100 ng) into 9–13 cells. 2 days post-transfection, the cells were harvested, and the
luciferase activity was measured. (E) The mutations introduced into the AP-1 binding sites in pDR4/2632 and Sp1-binding sites in pDR5/2560 are
illustrated. (F) The Sp1-specific siRNA or the control siRNA (100 pmol) was transfected into 9–13 cells cultured in 6-well plates. 2 days post-
transfection, the Sp1 and DR5 RNA and protein levels were measured using real-time PCR and western blot analyses, respectively. (G) A plasmid
expressing HCV NS3/4A, NS4B, NS5A or NS5B (600 ng) was individually co-transfected with either DR4/2632 or DR5/2560 (100 ng) and the Renilla
luciferase reporter plasmid (100 ng) into Huh7 cells. 2 days post-transfection, the cells were harvested, and luciferase activity was measured. The data
are presented with the SD from three independent experiments, and statistical significance was calculated by t test or two-way ANOVA, * indicates a p
value less than 0.05.
doi:10.1371/journal.pone.0037700.g005
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expression of DR4 and DR5 is elevated in a JFH-1 infected
hepatoma cell line, named by LH86 [4,23]. Therefore, the
mechanism underlying the HCV-mediated regulation of the
TRAIL receptors remains unclear.
MEK1 is a dual specificity kinase that phosphorylates and
activates ERK1/2 by phosphorylating threonine and tyrosine
residues [34], and ERK1/2 can phosphorylate Sp1 [29]. Schmitz
and colleagues (2008) reported that the increased phosphorylation
of ERK1/2 (pERK) is correlated with HCV-induced cirrhosis and
that approximately half of HCV-infected HCCs are pERK1/2
positive [39]. These findings are similar to the results in this study
where phosphorylation of MEK1 was found to be increased in 9–
13 cells and JFH-1 infected Huh7.5.1 cells (Figs. 7A and 7B),
suggesting that MEK1/ERK are activated by HCV. Moreover,
the current study demonstrates that the inhibition of MEK1
activity or expression reverses the HCV-mediated up-regulation of
DR4 and DR5 (Figs. 7C, 7D and 7E). JNK can also phosphorylate
Sp1 to increase the stability of Sp1 [40]. The present study showed
that the over expression of MEKK1, which can strongly activate
JNK, did not increase DR5 transcription but slightly increased
DR4 transcription (Fig. 6C). Bild et al. (2002) reported that the
over expression of MEKK1 can induce expression of DR4 and
that MEKK1 can increase DR4 expression at the RNA level
approximately 1.5 fold [41]. In the present study, MEK1 increased
the DR4 promoter activity to a greater extent. Treating 9–13 cells
with the JNK inhibitor, SP600125, did not abolish the expression
of DR4 or DR5. These results indicate that the HCV-induced up-
regulation of DR4 was mediated by MEK1 but not MEKK1.
The results of the present study showed that Sp1 activity was
critical for HCV-induced up-regulation of DR5, but we were
unable to identify the transcription factor that controls DR4
transcription in 9–13 cells. Moreover, point mutations at the two
putative AP-1 binding sites in the DR4 promoter (2410/2404 bp
or 2552/2545 bp) did not influence the activity of the DR4
promoter (Fig. 5B). Previous studies have demonstrate that DR4 is
regulated by both NF-kB and p53 [42,43]. However, NF-kB
activity was not significantly different in 9–13 and Huh7 cells
(Fig. 6A). Importantly, the Huh7 cell line carries a single p53
mutation (A:TRG:C at codon 220) and is p53 defective [44,45].
Thus, it is possible that other transcription factors are involved in
the HCV-mediated up-regulation of DR4, and further research is
needed to identify the transcription factors involved in HCV-
regulated DR4 transcription.
Because both the sub genomic replicon and full-length virus
increased the expression of DR4 and DR5, the structural proteins
may not be involved in the regulation of the TRAIL pathway. We
examined which HCV nonstructural proteins contributed to the
up-regulation of DR4 and DR5. Although we found that the
expression of NS3/4A or NS4B had a modest effect on the DR4
promoter activity and that the expression of NS3/4A, NS4B or
NS5A had a similar modest up-regulation of the DR5 promoter
activity, these effects were much weaker than those observed when
the replicon was present (Fig. 5G). These results suggest that either
the replication of the HCV genome or multiple HCV proteins
may be needed to fully induce DR4 and DR5 expression.
Treating cells with the MEK1 inhibitor, PD98059, enhances
HCV replication [37,38]. Moreover, the Ras-ERK pathway has
an important role in the IFN-c and oxidative stress-induced anti-
HCV effect, and activation of the Ras-ERK pathway either by
EGF stimulation or over expression of Ras can suppress HCV
replication [46,47]. Therefore, the Ras-ERK pathway is a negative
regulator of HCV replication. However, Gretton et al. (2009)
reported that different MEK1/2 inhibitors have different effects
on HCV replication: PD98059 causes a modest increase in HCV
replication, but U0126 and PD184352 inhibit HCV replication.
Moreover, they showed that neither EGF nor a high concentration
of PD98059 affects HCV NS5A protein expression in cells
transfected with the HCV replicon and that the transfection of
a dominant negative MEK1 mutant inhibits HCV replication
[48]. These results demonstrate that low MEK/ERK activity is
required for HCV replication because PD98059 is less effective
than U0126 in inhibiting MEK/ERK activity. In this study, we
found elevated MEK1 activity in HCV-infected cells (Fig. 7B).
Figure 6. Over expression of MEK1 activates the DR4 and DR5
promoters. (A) The AP-1, Sp1 or NF-kB luciferase reporter plasmid
(100 ng) was co-transfected with the Renilla luciferase reporter plasmid
(100 ng) into 9–13 or Huh7 cells cultured in 24-well plates. 2 days post-
transfection, luciferase activity was measured. (B and C) pMEK1-pRK or
pMEKK1-pRK (600 ng) and the Renilla luciferase reporter plasmid
(100 ng) were co-transfected with the (B) AP-1 or Sp1 reporter plasmid
(100 ng) or (C) the indicated DR4 or DR5 reporter plasmid (100 ng) into
Huh7 cells cultured in 24-well plates. 2 days post-transfection, luciferase
activity was measured. The data are presented with the SD from three
independent experiments, and statistical significance was calculated by
t test, * indicates a p value less than 0.05.
doi:10.1371/journal.pone.0037700.g006
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37700Partial inhibition of MEK1 by PD98059 or a siRNA significantly
increased the replication of JFH-1 (Fig. 8). Together, these results
suggest that MEK1 with high activity is a negative regulator of
HCV and is stimulated by HCV infection. This study demon-
strates that HCV replication sensitizes host cells to TRAIL-
induced apoptosis by up-regulating the DR4 and DR5 via
a MEK1-dependent pathway. These findings may help to
elucidate the mechanism underlying the HCV-mediated sensiti-
zation of cells to TRAIL and, thus, may help to further unravel the
pathogenesis of HCV infection and provide new therapeutic
targets for the treatment of HCV infection.
Materials and Methods
Plasmids and reagents
Reporter plasmids were constructed using the pGL3 vector
containing a firefly luciferase open reading frame (Promega). The
human DR4 and DR5 promoters were cloned from DNA
extracted from Huh7 cells using the PUREGENE DNA Purifi-
cation System, as recommend by the manufacturer (Gentra). PCR
for the DR4 promoter was performed with following sense
primers: DR4/21156 (sense, 59-GCAGATCTGCCCGGTC-
GAAAAGAGTCTTTTCAA-39), DR4/2632 (sense, 59-
GCCTCGAGCCAAAACAGTGAAACCCCCGTCTC-39),
DR4/2541 (sense, 59-GCCTCGAGGCTGAGGCAG-
GAAAATCGCTTGAAC-39), DR4/464 (sense, 59-
GCCTCGAGGGGCGACAGAGCTTGACTCCATCTC-39),
DR4/2384 (sense, 59-GCCTCGAGGGAGGCCG-
TAAAAGCCTCTTAGAGG-39), and DR4/2349 (sense, 59-
GCCTCGAGCAGTGGCCTCTGTGTCCTTCATTCC-39).
The following antisense primer was used for all of the above
reactions for DR4: 59-GCAAGCTTCATCCTGCCAGGT-
CAATCCAAGAAG-39. PCR for the DR5 promoter was
performed with following sense primers: DR5/21192 (sense, 59-
GCCTCGAGCACCAGAAGGAAGAAACTCCGAACA-39),
DR5/2560 (sense, 59-GCCTCGAGAGAGAAGGAGAGAACA-
GAAGGGGCA-39), DR5/2220 (sense, 59-GCCTCGA-
GAGTTGCACATTGGATCTGATTCGCC), and DR5/2115
(sense, 59-ACCTCGAGGGCCGGAGAACCCCG-
CAATCTCTGC). The following antisense primer was used for
all of the above reactions for DR5: 59-GCAAGCTTGGCGG-
TAGGGAACGCTCTTATAGTC-39. Point mutations were in-
troduced into pDR4/2632 and pDR5/2560 using PCR-based
site-directed mutagenesis and the following primers: 59-ATCC-
CAGTTACTTGGGAGGC-39 and 59-GCCTCCCAAG-
CAGCTGGGAT-39 for the 2552/2545 AP-1 binding site in
DR4 promoter to generate pDR4/2632/2547m, 59-
GGCAGGCTGAATTGCTCGCC-39 and 59-GGCGAG-
CAATTCAGCCTGCC-39 for the 2410/2404 AP-1 binding
site in DR4 promoter to generate pDR4/2632/2410m, 59-
ATTCGCCATGTACCGAATGA-39 and 59-TCATTCGGTA-
CATGGCGAAT-39 for the 2195/2189 Sp1-binding site in the
DR5 promoter to generate pDR5/2560/2195m and 59-
AGCCGCGATGATCCAAGTCA-39 and 59-TGACTTGGTA-
CATCGCGGCT-39 for the 2149/2143 Sp1-binding site in the
DR5 promoter to generate pDR5/2560/2149m. The pDR4/
2632/dm plasmid was mutated both at the 2552/2547 and
2410/2404 sites in the DR4 promoter and the pDR5/2560/dm
plasmid was mutated both at the 2195/2189 and 2149/2143
sites in the DR5 promoter (the ATG translation initiation site of
DR4 and DR5 was designed as +1). The Sp1 reporter plasmid was
constructed by introducing five Sp1-binding sites (59-
Figure 7. HCV-mediated increased DR4 and DR5 expression is MEK1 dependent. Huh7 and 9–13 cell lysates (A) or Huh7.5.1 and JFH-1
infected Huh7.5.1 cell (MOI 0.02) lysates (B) were subjected to western blot analyses using antibodies against phospho-MEK1 or MEK1. (C) Untreated
9–13 cells or 9–13 cells treated with 100 mM PD98059, 100 mM SP600125 or DMSO for 2 days were harvested and subjected to western blot analyses
using antibodies against DR4 or DR5. (D) The MEK1-specific siRNA or control siRNA (100 pmol) was transfected into 9–13 cells cultured in 6-well
plates. 2 days post-transfection, the expression of MEK1, DR4 and DR5 was determined using western blot analyses. (E) Huh7.5.1 cells were
transfected with the MEK1-specific siRNA or control siRNA and infected with JFH-1 (MOI 0.02) 6 hr post transfection. 3 days post infection, the
expression of MEK1, DR4 and DR5 was determined using western blot analyses. (F) Huh7.5.1 cells were transfected with indicated siRNA, and the
expression of MEK1 was measured by using western blot 2 days later. (G) 9–13 cells were transfected with MEK1 siRNA1, MEK1 siRNA2 or scramble
RNA, 3 days post transfection, cells were treated indicated concentration of TRAIL for 2 hr, and stained with annexin V and PI. The proportion of
apoptotic cells was analyzed by using flow cytometry. (H) Huh7.5.1 cells were transfected with MEK1 siRNA1, MEK1 siRNA2 or scramble RNA, 6 hr
later, cells were infected with JFH-1 (MOI 0.5), 3 days post infection, cells were treated indicated concentration of TRAIL for 2 hr, and stained with
annexin V and PI. The proportion of apoptotic cells was analyzed by using flow cytometry. The data are presented with the SD from three
independent experiments, and statistical significance was calculated by two-way ANOVA, * indicates a p value less than 0.05.
doi:10.1371/journal.pone.0037700.g007
Figure 8. Inhibition of MEK1 increases HCV replication. Huh7.5.1 cells were transfected with a MEK1-specific siRNA (A) or treated with 10 mM
PD98059 (B) and 6 hr post-transfection or treatment, infected with JFH-1 (MOI 0.02). 3 days post-infection, the expression of the HCV core protein
was detected using western blot.
doi:10.1371/journal.pone.0037700.g008
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plasmid (pAP-1-pGL3), NF-kB reporter plasmid (pNF-kB-pGL3),
MEK1 expression plasmid (pMEK1-pRK) and MEKK1 expres-
sion plasmid (pMEKK1-pRK) were kindly provided by Dr.
Hongbin Shu from Wuhan University. The MEK1 inhibitor,
PD98059, was purchased from Cell Signaling Technology, and
the JNK inhibitor, Sp600125, was purchased from Sigma.
Cell lines, virus and DNA transfection
The human hepatoma cell lines, Huh7 and 9–13, were kindly
provided by Dr. Ralf Bartenschlager from Universita ¨tsklinikum
Heidelberg. Both cell lines were cultured in DMEM supplemented
with 10% fetal bovine serum (GIBCO) at 37uC, and the 9–13 cells
were maintained in medium supplemented with 250 mg/mL G418
(Sigma). All transfection was performed using Lipofectamine 2000
(9–13 and Huh7 cells) (Invitrogen) or FuGENE HD (Huh7.5.1
cells) (Roche), as recommended by the manufacturer. JFH-1 and
Huh7.5.1 cells were kindly provided by Prof. Hongbin Shu
(Wuhan University, Wuhan, China). The virus titer was 10
4 and
10
6 ffu/mL, and Huh7.5.1 cells were infected at an MOI of 0.02
or 0.5.
Establishment of HCV-cured cells
HCV-cured cells were established according to the method
described by Blight et al. [49]. Briefly, 9–13 cells were treated with
100 IU/mL IFN-a for four passages. Clearance of the HCV
replicon was confirmed by the loss of G418 resistance and NS3/
4A expression.
Caspase 3 activity assay
A Caspase 3 Activity Assay Kit (Beyotime) was used to measure
caspase 3 activity. Huh7 and 9–13 cells were treated with 50 ng/
mL TRAIL for 2 hr, and the cells were then lysed. The caspase 3
substrate (Ac-DEVD-pNA) was then added to the samples, after
incubation at 37uC for 2 hrcaspase 3 activity was measured by
detecting the absorbance at 405 nm.
Luciferase activity assay
Cells cultured in 24-well plates were co-transfected with 50 or
100 ng of the Renilla luciferase reporter plasmid and 100 ng of the
indicated Firefly luciferase reporter plasmids. 2 days post-trans-
fection, cells were harvested and lysed in the a buffer containing
20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1%
Triton X-100 and a protease inhibitor cocktail (Calbiochem).
Firefly and Renilla luciferase activity was detected using a Dual
Luciferase Reporter Assay System (Promega), as recommended by
the manufacturer. Firefly luciferase activity was normalized using
Renilla luciferase activity.
Real-time PCR
Total cellular RNA was purified from cultured cells using
TRIZOL (Invitrogen), as recommended by the manufacturer.
Reverse transcription was performed using random primer and
Moloney murine leukemia virus reverse transcriptase (Promega),
and the cDNA was used as a template for real-time PCR. Real-
time PCR was performed using a SYBR master mix (TOYOBO)
and an ABI7300. The PCR conditions were as follows: 95uC for
60 s followed by 40 cycles of 95uC for 15 s, 60uC for 15 s, and
72uC for 45 s. The expression of DR4, DR5, Sp1 and GAPDH (as
an internal control) was measured in 9–13 and Huh7 cells using
the following primers: DR4 (sense, 59-
CTCGCAGTCCGCTTTCGTGT-39, and antisense, 59-CAG-
CATCAGAGTCGCAGTGG-39), DR5 (sense, 59-AA-
GACCCTTGTGCTCGTTGT-39, and antisense, 59-AGGTG-
GACACAATCCCTCTG-39), DcR1 (sense, 59-
GGTGTGGATTACACCAACGCTTC-39, and antisense, 59-
CTGACACACTGTGTCTCTGGTC-39), DcR2 (sense, 59-
CTGCTGGTTCCAGTGAATGACG-39, and antisense, 59-
TTTTCGGAGCCCACCAGTTGGT), Sp1 (sense, 59-ATT-
GAGTCACCCAATGAGAACAG-39, and antisense, 59-CAGC-
CACAACATACTGCCC-39), and GAPDH (sense, 59-CACT-
CAGCCGCATCTTCTTT-39, and antisense, 59-
ACGACCTAATCCGTTCACTC-39).
The DR4, DR5, DcR1, DcR2 and Sp1 levels in each sample
were normalized based on the GAPDH level in each sample.
RNA interference
The Sp1-specific siRNA was purchased from Santa Cruz (sc-
29487). The MEK1-specific siRNA was purchased from Gene-
pharma (sense, 59-GAGGUUCUCUGGAUCAAGUTT-39, and
antisense, 59-ACUUGAUCCAGAGAACCUCTT-39) and QIA-
GEN MEK1 siRNA1 (TTGTGAATAAATGCTTAATAA),
siRNA2 (CTGGAAGAATTCCTGAACAAA). The siRNA
(100 pmol/well) was transfected into cells cultured in 6-well plates
using Lipofectamine 2000 (Invitrogen) or 37.5 ng/well into cells
cultured in 24-well plates using Hiperfect transfection reagent
(QIAGEN). 2 days post-transfection, the RNA and protein levels
were measured using real-time PCR and western blot analyses,
respectively.
Induction of apoptosis by TRAIL
Cells were seeded (60–70% confluent) in 12-well plates.
Twenty-four hr after plating or 3 days post transfection and
infection the cells were treated with recombinant human TRAIL
(R&D Systems) for 2 hr. Alternatively, 9–13 cells were incubated
in the presence or absence of 20 mM Z-VAD-FMK (a pan-caspase
inhibitor; R&D Systems) for 1 hr prior to treatment with TRAIL.
Subsequently, the cells were harvested, washed with PBS and
stained with annexin V (Bender MedSystems), as recommended
by the manufacturer. The proportion of apoptotic cells was
determined using flow cytometry.
Western blot analysis
Cells were lysed in a buffer described above in ‘‘Luciferase
activity assay’’ section. After two freeze/thaw cycles, cell debris
was removed by centrifugation. Equal amounts of the protein
samples were resolved by 12% SDS-PAGE, and the proteins were
transferred onto a nitrocellulose membrane (Amersham Bios-
ciences). The membrane was probed using a polyclonal antibody
against HCV NS3/4A protein (produced by our laboratory), core
protein (Santa Cruz sc-57800), human DR4 (Abcam ab8414),
DR5 (Sigma D3938), Sp1 (Santa Cruz sc-59), MEK1 (Cell
Signaling Technology #2352), phospho-MEK1/2 (Cell Signaling
Technology #9121) or a mouse monoclonal antibody against b-
actin (Santa Cruz). Densitometric analyses were performed in
some results by showing the ratio to b-actin.
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